Regulatory T cells (Tregs) and beta-galactoside-binding protein (bGBP), a regulatory protein often found expressed at sites of immunological privilege, have similar functions. Their presence affects the outcome of harmful autoimmunity and cancers, including experimental autoimmune encephalomyelitis and malignant gliomas. Here we report a novel pathway by which Tregs express and utilize bGBP to control CD8 + T cell responses partially activating TCR signaling but blocking PI3K activity. As a result, this leads to a loss of p21 
, although Tr1 cells can utilize cell contact-dependent perforin/granzyme-mediated regulatory processes (Grossman et al., 2004; Gondek et al., 2005) . We have recently reported that granzymes are not expressed and not utilized by human peripheral blood Tregs (Baatar et al., 2007) . These Tregs belong to the memory-type CCR4-expressing cells that are already primed and efficiently suppress the proliferation of CD8 + T cells. Recently, it was proposed that beta-galactoside-binding protein (bGBP) is expressed by Tregs (Garin et al., 2007) , as well as activated T cells (Allione et al., 1998; Blaser et al., 1998) , to regulate T cells. bGBP is a 15 KDa monomeric form of homodimeric lectin-type protein Galectin-1 (Gal-1) which oligomerizes at concentrations greater than 7 lM (Cho and Cummings, 1996) . It is found often produced at sites of immunological 
